Towards new prognostic factors in diffuse large cell non-Hodgkin's lymphoma

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 993-996

  Salles, G ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030450480     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010522     Document Type: Editorial

References (53)

1. Salles G. Shipp M.A. Coiffier B. Chemotherapy of non-Hodgkin's aggressive lymphomas Semin Hematol 31 1994 46 69
2. The Internationa] Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 1993 987 994
3. Harris N.L. Jaffe E.S. Stein H. A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group Blood 84 1994 1361 1392
4. Coiffier B. Brousse N. Peuchmaur M. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen Ann Oncol 1 1990 45 50
5. Johnson P.W.M. Whelan J. Longhurst S. 2-Microglobulin: A prognostic factor in diffuse aggressive non-Hodgkin's lymphomas Br J Cancer 67 1993 792 797
6. Swan F. Velasquez W.S. Tucker S. A new serologic staging system for large-cell lymphomas based on initial 2-micro-globulin and lactate dehydrogenase levels J Clin Oncol 7 1989 1518 1527
7. Coiffier B. Gisselbrecht C. Vose J.M. Prognostic factors in aggressive malignant lymphomas. Description and validation of a prognostic index that could identify patients requiring a more intensive therapy J Clin Oncol 9 1991 211 219
8. Cowan R.A. Jones M. Harris M. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma Br J Cancer 59 1989 276 282
9. Coiffier B. Bryon P.A. Ffrench M. Intensive chemotherapy in aggressive lymphomas: Updated results of LNH-80 protocol and prognostic factors affecting response and survival Blood 70 1987 1394 1399
10. Dhaliwal H.S. Rohatiner A.Z.S. Gregory W. Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma Br J Cancer 68 1993 767 774
11. Grogan T.M. Miller T.P. Immunobiologic correlates in prognosis in lymphoma Semin Oncol 20 Suppl 5 1996 58 74
12. Shipp M.A. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has 'high-risk' disease Blood 83 1994 1165 1173
13. Offit K. Wong G. Filippa D.A. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma. Clinical correlations Blood 77 1991 1508 1515
14. Romaguera J.E. Pugh W. Luthra R. The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma Ann Oncol 4 1993 51 54
15. Levine E.G. Arthur D.C. Frizzera G. Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma Ann Intern Med 108 1988 14 20
16. Schouten H.C. Sanger W.G. Weisenburger D.D. Abnormalities involving chromosome 6 in newly diagnosed patients with non-Hodgkin's lymphoma Cancer Genet Cytogenet 47 1990 73 82
17. Cabanillas F. Pathak S. Grant G. Refractoriness to chemo-therapy and poor survival related to abnormalities of chro-mosome 17 and 7 in lymphoma Am J Med 87 1989 167 172
18. Rodriguez M.A. Ford R.J. Goodacre A. Chromosome 17p and p53 changes in lymphoma Br J Haematol 79 1991 575 582
19. Offit K. Lococo F. Louie D.C. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma N Engl J Med 331 1994 74 80
20. Bastard C. Deweindt C. Kerckaert J.P. LAZ3 rearrangements in non-Hodgkin's lymphoma: Correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients Blood 83 1994 2423 2427
21. Cowan R.A. Harris M. Jones M. DNA content in high and intermediate grade non-Hodgkin's lymphoma. Prognostic significance and clinicopathological correlations Br J Cancer 60 1989 904 910
22. Akerman M. Brandt L. Johnson A. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis Br J Cancer 55 1987 219 223
23. Joensuu H. Ristamäki R. Söderström K.-O. Effect of treatment on the prognsotic value of S-phase fraction in non-Hodgkin's lymphoma J Clin Oncol 12 1994 2167 2175
24. Slymen D.J. Miller T.P. Lippman S.M. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma J Clin Oncol 8 1990 986 993
25. Jakic-Razumovic J. Tentor D. Petrovecki M. Nucleolar organiser regions and survival in patients with non-Hodgkin's lymphomas classified by the working formulation J Clin Pathol 46 1993 943 947
26. Klemi P.J. Alanen K. Jalkanen S. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in non-Hodgkin's lymphoma Br J Cancer 66 1992 739 743
27. Kamel O.W. Lebrun D.P. Davis R.E. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A2. Correlation with Ki-67 labeling Am J Pathol 138 1991 1471 1477
28. Miller T.P. Grogan T.M. Dahlberg S. Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial Blood 83 1994 1460 1466
29. Erikstein B.K. Holte H. Kvaloy S. Expression of CD18 (integrin 2 chain) correlates with prognosis in malignant B-cell lymphomas Br J Haematol 83 1993 392 398
30. Jalkanen S. Joensuu H. Soderstrom K.O. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma J Clin Invest 87 1991 1835 1840
31. Pals S.T. Horst E. Ossekoppele G.J. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma Blood 73 1989 885 888
32. Koopman G. Griffioen A.W. Ponta H. Cd44 splice variants: Expression on lymphocytes and in neoplasia Res Immunol 144 1993 750 754
33. Salles G. Zain M. Jiang W.M. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: Characterization and comparison with normal activated B-cells and epithelial malignancies Blood 82 1993 3539 3547
34. Stauder R. Eisterer W. Thaler J. Cd44 variant isoforms in non-Hodgkins lymphoma - a new independent prognostic factor Blood 85 1995 2885 2899
35. Kossakowska A.E. Urbanski S.J. Huchcroft S.A. Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kda gelatinase (type-IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs Oncol Res 4 1992 233 240
36. Miller T.P. Lippman S.M. Epier C.M. HLA-DR (la) immune phenotype predicts outcome for patients with diffuse large cell lymphoma J Clin Invest 82 1988 370 376
37. O'Keane J.C. Mack C. Lynch E. Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN-3 antibody staining. An Eastern Cooperative Oncology Group (ECOG) study Cancer 66 1990 1147 1153
38. Seymour J.F. Talpaz M. Cabanillas F. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma J Clin Oncol 13 1995 575 582
39. Blay J.Y. Burdin N. Rousset F. Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor Blood 82 1993 2169 2174
40. Salles G. Bienvenu J. Bastion Y. Elevated circulating alpha-TNF and soluble TNF-receptor levels are associated with adverse prognostic factors and poor outcome in lymphoma patients Br J Haematol 93 1996 352 359
41. Warzocha K. Salles G. Bienvenu J. The tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients J Clin Oncol 1997 in press
42. Pileri S.A. Sabattini E. Falini B. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas Histopathology 19 1991 131 140
43. Yuen A.R. Sikic B.I. Multidrug resistance in lymphomas J Clin Oncol 12 1994 2453 2459
44. Hermine O. Haioun C. Lepage E. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkins lymphoma Blood 87 1996 265 272
45. Kramer M.H.H. Hermans J. Parker J. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma - a population-based study J Clin Oncol 14 1996 2131 2138
46. Hill M.E. Maclennan K.A. Cunningham D.C. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma - a british national lymphoma investigation study Blood 88 1996 1046 1051
47. Gribben J.G. Freedman A.S. Neuberg D. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma N Engl J Med 325 1991 1525 1533
48. Gribben J.G. Neuberg D. Freedman A.S. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood 81 1993 3449 3457
49. Limpens J. Dejong D. Van Krieken J.H.J.M. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia Oncogene 6 1991 2271 2276
50. Liu Y. Hernandez A.M. Shibata D. BCL2 translocation frequency rises with age in humans Proc Natl Acad Sci USA 91 1994 8910 8914
51. Limpens J. Stad R. Vos C. Lymphoma-associated translocation t(14–18) in blood B-cells of normal individuals Blood 85 1995 2528 2536
52. Jacobson J.O. Wilkes B.M. Kwiatkowski D.J. bcl-2 re-arrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features Cancer 72 1993 231 236
53. Offit K. Koduru P.R.K. Hollis R. 18q21 Rearrangement in diffuse large cell lymphoma - incidence and clinical significance Br J Haematol 72 1989 178 183